Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study

PURPOSE: Gastric cancer (GC) is one of the most frequently diagnosed cancers and one of the leading causes of cancer deaths worldwide, especially in eastern Asia and China. Anti-PD-1 immune checkpoint inhibitors, Pembrolizumab and Nivolumab, have been approved for the treatment of locally advanced o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tao, Liu, Tingting, Zhao, Lei, Liu, Lu, Zheng, Xuan, Wang, Jinliang, Zhang, Fan, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850086/
https://www.ncbi.nlm.nih.gov/pubmed/36686795
http://dx.doi.org/10.3389/fonc.2022.976078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850086/
https://www.ncbi.nlm.nih.gov/pubmed/36686795
http://dx.doi.org/10.3389/fonc.2022.976078

Ejemplares similares